

# Performance

Learn more about our  
performance on our [Investor site](#).

# Financial Performance

Three-year summary for the years ended December 31

(Millions, Except Per Share Data)				% Change	
	2024	2023	2022	24/23	23/22
Revenues <sup>(a)</sup>	\$63,627	\$59,553	\$101,175	7	(41)
Reported net income <sup>(b)</sup>	\$8,031	\$2,119	\$31,372	*	(93)
Reported diluted EPS <sup>(b)</sup>	\$1.41	\$0.37	\$5.47	*	(93)
Adjusted income <sup>(c)</sup>	\$17,716	\$10,501	\$37,717	69	(72)
Adjusted diluted EPS <sup>(c)</sup>	\$3.11	\$1.84	\$6.58	69	(72)
Net cash provided by operating activities	\$12,744	\$8,700	\$29,267	46	(70)
Cash dividends paid	\$9,512	\$9,247	\$8,983	3	3

(a) In the first quarter of 2024, we reclassified royalty income from *Other (income)/deductions—net* and began presenting *Royalty revenues* as a separate line item within *Total revenues* in our consolidated statements of operations. Prior-period amounts have been recast to conform to the current period presentation.

(b) Reported net income is defined as *Net income attributable to Pfizer Inc. common shareholders* in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Reported diluted earnings per share (EPS) is defined as diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.

(c) Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP *Net income attributable to Pfizer Inc. common shareholders* and *EPS attributable to Pfizer Inc. common shareholders—diluted* before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. The Adjusted income and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and diluted EPS, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. See the *Non-GAAP Financial Measure: Adjusted Income* section of [Management’s Discussion and Analysis of Financial Condition and Results of Operations](#) in Pfizer’s 2024 Annual Report on Form 10-K for an explanation of how management uses these non-GAAP measures, reconciliations to the most directly comparable U.S. GAAP measures and additional information.

Detailed information on our financial and operational performance can be found in our 2024 Annual Report on Form 10-K.



# Top 10 Medicines and Vaccines

Take a look at our breakdown of the top medicines and vaccines by revenue from 2024.<sup>1</sup>

● **\$7,366 million**  
ELIQUIS® (apixaban)<sup>2</sup>

● **\$6,411 million**  
PREVNAR® Family<sup>3</sup>

● **\$5,716 million**  
PAXLOVID® (nirmatrelvir tablets and ritonavir tablets)

● **\$5,451 million**  
VYNDAQEL® Family<sup>4</sup>

● **\$5,353 million**  
COMIRNATY®<sup>5</sup>


● **\$4,367 million**  
IBRANCE® (palbociclib)

● **\$2,039 million**  
XTANDI® (enzalutamide)<sup>6</sup>

● **\$1,588 million**  
PADCEV® (enfortumab vedotin-ejfv)

● **\$1,263 million**  
NURTEC ODT®/VYDURA® (rimegepant)

● **\$1,168 million**  
XELJANZ® (tofacitinib)



<sup>1</sup> In the first quarter of 2024, we began presenting *Royalty revenues*, which were previously reported in *Other (income)/deductions—net*, as a separate line item within *Total revenues* in our consolidated statements of operations.

<sup>2</sup> ELIQUIS reflects alliance revenues and product revenues.

<sup>3</sup> PREVNAR Family includes Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult).

<sup>4</sup> VYNDAQEL Family includes global revenues from VYNDAQEL, as well as revenues for VYNDAMAX in the U.S. and VYNMAC in Japan.

<sup>5</sup> COMIRNATY refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine; Comirnaty (COVID-19 Vaccine, mRNA) original monovalent formula; the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5); the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2023-2024 Formula; Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula; Comirnaty Original/Omicron BA.1; Comirnaty Original/Omicron BA.4/BA.5; Comirnaty Omicron XBB.1.5; Comirnaty JN.1 and Comirnaty KP.2.

<sup>6</sup> XTANDI primarily reflects alliance revenues and royalty revenues.

View the interactive graph on the [Annual Review site](#).